The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.
Linthicum, MD-The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.
Peyronie’s disease (PD) is defined by the guideline panel “as an acquired penile abnormality characterized by fibrosis of the tunica albuginea, which may be accompanied by pain, deformity, erectile dysfunction, and/or distress.” In published studies, the condition’s prevalence ranges from 0.5 to 20.3%, a wide variation that depends on individual study factors, including how PD is defined and how men are queried. The rate may be higher in men with comorbid conditions, the panel wrote, and recent studies suggest that its prevalence has been historically underestimated.
Dr. Burnett“I think a guideline in Peyronie’s disease is timely, with the development of therapies that seem to meet level 1 evidence. Certainly this is a condition that we’re recognizing by epidemiologic studies has high prevalence and high significance. It impacts a lot of men,” said Arthur L. Burnett, II, MD, MBA, professor of urology at Johns Hopkins University School of Medicine, Baltimore.
The guideline was initially presented at the AUA annual meeting in New Orleans and was subsequently published in the Journal of Urology (2015; 194:745–53). Its evidence-based statements are divided into sections on diagnosis and treatment. Highlights include the following.
Next: Dr. Burnett discusses guideline in video
“The urologist or clinician should be prepared to carry out a proper evaluation of the patient, and that includes clinical history taking, physical examination, and counseling the patient,” Dr. Burnett told Urology Times.
Among the specific recommendations:
Among the clinical principles for first-line treatment are the following:
“I think the guideline brings awareness to the condition overall,” Dr. Burnett said, “and it should help guide us about where we do have gaps in our knowledge and gaps in the care we currently have available and may help derive future directions for treating patients with Peyronie’s disease.”
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.